Please login to the form below

Not currently logged in
Email:
Password:

BiTE

This page shows the latest BiTE news and features for those working in and with pharma, biotech and healthcare.

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

Amgen already has its own antibody technology – known as BiTE – which enables the identification and development of bispecific T cell engager antibodies. ... Teneobio’s own novel T cell engager platform will complement the BiTE platform, Amgen said

Latest news

More from news
Approximately 1 fully matching, plus 104 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 19 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...